Eric Sullivan Net Worth

The estimated Net Worth of Eric Sullivan is at least 1.68 百万$ dollars as of 3 August 2017. Eric Sullivan owns over 861 units of TCR2 Therapeutics stock worth over 9,056$ and over the last 10 years Eric sold TCRR stock worth over 1,675,421$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Eric Sullivan TCRR stock SEC Form 4 insiders trading

Eric has made over 25 trades of the TCR2 Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Eric exercised 861 units of TCRR stock worth 33,123$ on 3 August 2017.

The largest trade Eric's ever made was selling 6,787 units of TCR2 Therapeutics stock on 29 June 2017 worth over 739,512$. On average, Eric trades about 888 units every 26 days since 2014. As of 3 August 2017 Eric still owns at least 6,119 units of TCR2 Therapeutics stock.

You can see the complete history of Eric Sullivan stock trades at the bottom of the page.

What's Eric Sullivan's mailing address?

Eric's mailing address filed with the SEC is 100 BINNEY STREET, , CAMBRIDGE, MA, 02142.

Insiders trading at TCR2 Therapeutics

Over the last 6 years, insiders at TCR2 Therapeutics have traded over 15,820,150$ worth of TCR2 Therapeutics stock and bought 4,788,512 units worth 65,684,711$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Kevin Ctang Capital Managem...、Ansbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of 229,829$. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth 86,000$.

What does TCR2 Therapeutics do?

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Eric Sullivan stock trades at Bluebird bio Inc、TCR2 Therapeutics

TCR2 Therapeutics executives and stock owners

TCR2 Therapeutics executives and other stock owners filed with the SEC include:

• Garry Menzel,
  President, Chief Executive Officer, Director
• Alfonso Cardama,
  Chief Medical Officer
• Mayur Somaiya,
  Chief Financial Officer
• Dr. Garry E. Menzel M.B.A., Ph.D.,
  Pres, CEO & Director
• Dr. Alfonso Quintás Cardama M.D.,
  Chief Medical Officer
• Mayur Amrat Somaiya,
  Chief Financial Officer
• Dr. Patrick A. Baeuerle Ph.D.,
  Founder & Member of the Advisory Board
• Carl Mauch,
  IR Contact Officer
• Stephen Webster,
  Independent Director
• Neil Gibson,
  Independent Director
• Andrew Allen,
  Independent Director
• Axel Hoos,
  Director
• Patrick Baeuerle,
  Director
• Robert Hofmeister,
  Chief Scientific Officer
• Angela Justice,
  Chief People Officer
• Ansbert Gadicke,
  Independent Chairman of the Board
• Dr. Rosemary Harrison Ph.D.,
  Chief Bus. & Strategy Officer
• Dr. Robert Hofmeister Ph.D.,
  Chief Scientific Officer
• Stephen Turkowiak M.B.A.,
  VP of Fin. & Treasurer
• Gregg McConnell M.B.A.,
  Head of Bus. Devel.
• Dr. Angela Justice Ph.D.,
  Chief People Officer
• Margaret Siegel J.D.,
  VP & Head of Legal & Corp. Sec.
• Peter Olagunju,
  Chief Technical Officer
• Eric Sullivan,
  Chief Financial Officer
• Oncology Impact Fund L.P.On...,
  
• Morana Globeways Holdings L...,
  
• Morana Globeways Holdings I...,
  
• Morana Globeways Holdings L...,
  
• Morana Globeways Holdings L...,
  
• Oncology Impact Fund L.P.On...,
  
• Morana Globeways Holdings L...,
  
• Investment Ltd China Molybd...,
  
• Sun States Fund, L.P.Mpm As...,
  
• Group, Llc Green Jeremy Red...,
  
• Bio Ventures 2014, L.P.Fole...,
  
• Shawn Tomasello,
  Director
• Peter Olagunju,
  Chief Operating Officer
• Priti Hegde,
  Director
• Rosemary Harrison,
  Chief Business & Strategy
• Kevin Ctang Capital Managem...,
  
• Asset Management Llcevnin L...,